ITGAM and neoplasm: As NK-cells and F4/80+ macrophages account for most of the CD11b+ cells in these treatment groups (Fig 4B–4C), it is possible that the quality rather than quantity of tumor-infiltrating myeloid cells determines if tumors are rendered sensitive to killing by cytotoxic T-cells.